Ntie-Kang Fidele, Yong Joseph N, Owono Owono Luc C, Sippl Wolfgang, Megnassan Eugene
CEPAMOQ, Faculty of Science, University of Douala, P.O. Box 8580, Douala, Cameroon.
Curr Med Chem. 2014;21(30):3466-77. doi: 10.2174/0929867321666140706144933.
Based on the global burden of tuberculosis and resistant strains that have recently emerged, not responding to existing therapies, it has become urgent to search for new remedies against this global human plague that has been compounded by HIV co-infection. Thus, the search for new drugs against the disease-causing agent, Mycobacterium tuberculosis (MTB), is an ongoing effort. This review discusses the state-of-the-art in anti-tuberculosis pathogenesis and anti-TB drug research, identifying some of the challenges being faced by researchers in the field and sheds light on possible ways forward, particularly in low-income countries.
基于全球结核病负担以及最近出现的对现有疗法无反应的耐药菌株,在与艾滋病毒合并感染使这一全球人类疫病更加复杂的情况下,寻找针对这种疫病的新疗法已变得刻不容缓。因此,寻找针对致病原结核分枝杆菌(MTB)的新药是一项持续不断的工作。本综述讨论了抗结核发病机制和抗结核药物研究的最新进展,指出了该领域研究人员面临的一些挑战,并阐明了可能的前进方向,特别是在低收入国家。